Outcomes and Clinical Characteristics of the Compassionate Use of Plitidepsin for Immunocompromised Adult Patients with COVID-19

Aguareles, José; Fernández, Paula Villares; González, María Maravillas Carralón; Forné, Carles; Ballesteros, Eva María Martí; Fernández, Virginia Pradillo; Fernández, Gabriel Sotres; Delangue, Teresa García; LaPetra, Rocío García de Viedma; Manzano, María Dolores Sánchez; Montero, Carolina Gutierrez; Coca, Marta García; Ruiz, Daniel; Puertas, Ruth Barrena; Pinilla, Jose Manuel Luque; Lloris, Raquel; Stefan, Xavier Erik Luepke; López, José Antonio; Doñaque, José María Jimeno; Vasco, Pablo Guisado

doi:10.2139/ssrn.4316842

Cited by 1 publication

(1 citation statement)

References 14 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plitidepsin treatment was well-tolerated, with only two grade 3 treatment-related adverse events (AEs): hypersensitivity and diarrhea [8]. Plitidepsin's tolerability as a rescue treatment has also been demonstrated in 33 immunocompromised patients with persistent COVID-19 who were unsuitable for other antiviral treatments [9].…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2-Related Persistent Pulmonary Affection Case in A 55-Year-Old Gastric MALT Lymphoma Patient on Rituximab

Landete

2023

IJCCR

View full text Add to dashboard Cite

Following a mild symptomatic SARS-CoV-2 infection, a 55-year-old patient with gastric MALT lymphoma, currently treated with rituximab, experienced persistent symptoms. Over subsequent months, the patient exhibited low-grade fever, dyspnea, and progressive desaturation, leading to respiratory failure necessitating home oxygen therapy. A PCR test confirmed SARS-CoV-2 infection, prompting suspicion of persistent COVID-19. Imaging and biopsy results were consistent with cryptogenic organizing pneumonia (COP), but the patient showed no response to treatment, including corticosteroids and immunosuppressants. Remdesivir treatment yielded partial improvement but failed to achieve full resolution. Plitidepsin (2.5 mg/day for 3 days) under compassionate use led to negative PCR tests and normal respiratory function restoration within 3 days after treatment. SARS-CoV-2's impact on immunocompromised patients is concerning due to unique clinical features, challenges in viral clearance and immunization, and varied responses to approved treatments. A phase II clinical trial is underway to assess plitidepsin's efficacy in immunocompromised COVID-19 adults requiring hospital care.

show abstract

Section: Introductionmentioning

confidence: 99%